Abstract: An additive is disclosed for use with existing hair coloring products that combines multiple hair dye sources and classifications to create a single precise color tone on demand. The additive salvages chemical parts from existing hair coloring products to create a multitude of new hair coloring options. The additive perfects the dye diffusion process using physics, electrochemical technology and chemical screening technology. The resultant additive mixed with an existing hair product solves many of the problems within the hair coloring industry and enhances safety through lower toxicity.

Abstract: A foaming skin cleanser formulation comprising silver, stearic acid, myristic acid, linoleic acid, propanediol, carbomer, polyquarternium-39, cocamidopropyl hydroxysultaine, pomegranate sterols (cholesterol), Coco-caprylate/caprate, Cocos nucifera, Sodium Cocoyl Isethionate, and mixtures and combinations thereof.

Abstract: The present disclosure relates to, inter alia, a formulation in a package, the formulation comprises one or more active agents and is co-mingled with a whipping agent prior to being filled under pressure into the package. The whipping agent is added in sufficient amounts to be dispersed in the formulation. The pressurized package is under sufficient pressure suitable to maintain the whipping agent dispersed in the formulation; and the pressurized package is under sufficient pressure to expel the formulation as a whipped formulation upon application of external force on the formulation in the package.

Abstract: A rheological solid composition comprising a crystallizing agent and an aqueous phase.

Abstract: Disclosed is an antidandruff composition comprising low amounts of piroctone olamine which synergistically interacts with benzoic acid or a salt thereof and itaconic acid or an ester thereof. The composition may be used for personal cleansing and is especially preferred to be delivered as a shampoo or hair conditioner.

Abstract: A process for preparing an opaque composition using ethylene glycol distearate including the steps of providing a starting composition including A) from 0.5 parts by weight to 15 parts by weight of at least one surfactant, B) from 0.5 parts by weight to 15 parts by weight of at least one emulsifier, C) from 10 parts by weight to 30 parts by weight ethylene glycol distearate, and D) from 20 parts by weight to 85 parts by weight water; b) stirring the starting composition at a temperature in a range from 60° C. to 100° C.; and c) cooling to a temperature in a range from 5° C. to 55° C. to obtain the opaque composition.

Abstract: Disclosed is a personal care composition comprising: (a) a cationic or nonionic surfactant; (b) a high melting point fatty compound having a melting point of from 25oC to 60oC (c) a solid organic compound having a water solubility of lower than 25 g per 1 liter water, and having a melting point of exceeding 60oC, and also having a specific Alog P; (d) a first liquid oily compound other than a second liquid oily compound, wherein the first liquid oily compound has a water solubility of 10 g per 1 liter water or less, wherein a mixture of all the first liquid oily compounds included in the composition has a di-electric constant of from about 5 to about 10, and wherein the weight ratio of the solid organic compound to the first liquid oily compound is from about 1:1 to about 1:10; and (e) an aqueous carrier, wherein the composition comprises 0.1% or less of a second liquid oily compound having a higher AlogP of 7.0 or higher.

Abstract: A cosmetic composition comprising, in a physiologically acceptable medium, at least: (1) a cosmetic agent consisting of galactomannans with molar masses of 5 kDa to 630 kDa, preferably between 5 and 120 kDa, more preferably between 8 and 80 kDa, and cross-linked sulfated galactans with molar masses of 7 kDa and 3000 kDa, preferably between 7 and 1100 kDa, more preferably between 8 and 200 kDa, and (2) a Theobroma cacao L bean hydrolysate, and its use in particular for maintaining the balance of the skin microbiota and promoting and/or improving the wear of make-up.

Abstract: The invention relates to a cosmetic process for treating keratin fibres, comprising: (i) a step of applying to the keratin fibres a cosmetic composition containing a polyvinyl alcohol polymer comprising:—an alcohol unit—optionally an acetate unit—a photocrosslinkable unit—a hydrophobic unit; (ii) a step of irradiating the composition on the keratin fibres to crosslink said polymer. The invention also relates to the novel polyvinyl alcohol polymer used in said process. The treated keratin fibres have good cosmetic properties in terms of a soft feel and disentangling, which properties are persistent after one or more shampoo washes.

Abstract: The subject of the present invention relates to a composition for dyeing keratin fibers, comprising: a) one or more copolymer(s) derived from the polymerization of at least one monomer of crotonic acid or crotonic acid derivative and of at least one vinyl ester monomer, b) at least one oil-in-water emulsion having a particle size D 50 of less than 350 nm and which comprises: a silicone mixture comprising (i) at least one polydialkylsiloxane comprising trialkylsilyl end groups, having a viscosity at 25° C. ranging from 40 000 to 100 000 mPa·s and (ii) at least one aminosilicone having a viscosity at 25° C. ranging from 1000 to 15 000 mPa·s and an amine number ranging from 2 to 10 mg of KOH per gram of aminosilicone; a surfactant mixture comprising one or more nonionic surfactants, said mixture having an HLB ranging from 10 to 16, and water and c) at least one pigment.

Abstract: The present invention relates to a composition in the form of a water-in-oil (W/O) emulsion comprising an oily phase and an aqueous phase, comprising: (a) at least one oil; (b) at least one organic lipophilic gelling agent; (c) at least one pigment coated with isopropyl titanium triisostearate; and (d) water; wherein the amount of the (b) lipophilic gelling agent is greater than 0% by weight and less than 5% by weight relative to the total weight of the composition, and the amount of the aqueous phase is at least 50% by weight relative to the total weight of the composition.

Abstract: A nanonization method for cannabidiol (CBD) includes following steps: the CBD is dissolved in a good solvent to obtain a CBD-good solvent solution, the CBD-good solvent solution is added to aqueous solution of a stabilizer to obtain mixed solution, the mixed solution is ultrasonicated followed by removing the good solvent by rotary evaporation from the mixed solution to obtain a nanosized CBD suspension. The stabilizer includes one or more selected from the group consisting of poloxamer, tween, polyoxyethylene alkyl ether, polyvinyl pyrrolidone, hydroxypropyl methyl cellulose and carboxymethyl chitosan. Particle size of the CBD is reduced in the nanonization method for the CBD through the nanonization of insoluble drugs to obtain the nanosized CBD suspension. In the nanosized CBD suspension, nanosized CBD has high solid content. The nanonization method for the CBD achieves solubilization of the CBD.

Abstract: The disclosure provides oral products, the oral products including a fleece material that includes fibers and a releasable component. In some embodiments, oral products as described herein may be in the form of a pouchless product including a fleece material having a releasable component associated therewith, or in the form of a pouched product including a fleece material having a releasable component associated therewith in the form of a pouch, containing a substrate material therein.

Abstract: Novel preventive treatment for COVID 19 and therapeutic treatment for early stages of COVID 19 or any other disease caused by SARS CoV 2. Pharmaceutical formulations and devices are disclosed to be able to implement these treatments. These treatments to prevent and alleviate the symptoms at early stages of COVID 19, the pandemic disease caused by SARS CoV 2. These treatments are based on the administration the nasal cavity and/or the lungs of solutions containing iota Carrageenan with or without the addition of xylitol as antiviral drug substances.

Abstract: Described herein are therapeutic pH responsive compositions comprising a block copolymer and a therapeutic agent useful for the treatment of cancer.

Abstract: Metastable liposomal formulations for hydrophobic drug delivery to a tissue or tissue lumen such the bladder have been developed. These are at least one micron in diameter and formed of one or more lipids having entrapped in the lipid a hydrophobic therapeutic, prophylactic or diagnostic agent. The greater stability of these liposomes, as well as the enhanced transfer of entrapped agent into the adjacent tissue, provides for better delivery, especially of hydrophobic agents such as tacrolimus which does not penetrate tissue well. The metastable liposomal formulations can be administered locally, preferably by instillation, or topically, for example, by spraying or painting, to a tissue or tissue lumen such as the bladder in need of treatment.

Abstract: A bioactive substance delivery system includes a bioactive substance comprising nucleic acid, and a bioactive substance carrier comprising a porous silica particle having a plurality of pores with a diameter of 5 nm to 100 nm, and having not less than 24 hours at which a ratio of absorbance is ½. The porous silica particles may be positively charged inside the pore at neutral pH.

Abstract: Nanoparticles and nanonetworks formed of these nanoparticles are provided. Methods for forming such nanoparticles and nanonetworks are also provided, as well as uses of the nanoparticles and/or nanonetworks, including their use for drug delivery.

Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.

Abstract: The present invention relates to a process for spray drying of a feed solution comprising semaglutide, said process comprising introducing the feed solution comprising semaglutide in a solvent into a spray dryer and introducing an atomising gas and a drying gas, characterised in that the spray dryer comprises a gas heater for the drying gas with an inner surface comprising iron and less than 18.5% chromium.

Abstract: The present invention relates to a method of producing a direct compression tablet composition comprising the step of processing ibuprofen, a hydrophilic polymer, and an inorganic excipient by an extrusion process to produce an extruded composition in which the ibuprofen forms a solid dispersion/solution within the hydrophilic polymer. The invention is particularly useful in preparing oral dissolvable tablets. Also provided are composition comprising an inorganic excipient and ibuprofen within a hydrophilic polymer.

Abstract: Provided herein are pharmaceutical compositions for oral administration comprising N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pirimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide or a pharmaceutically acceptable salt, hydrate, or solvate thereof as an active ingredient; and a combination of (i) a cellulose derivative and (ii) a sugar or polyol as diluents. The disclosed compositions are characterized by improved manufacturability, while maintaining the pharmaceutical benefits of minimizing the effect according to changes in pH environment in the stomach, possessing excellent stability, and exhibiting good bioavailability.

Abstract: The present invention relates to a nanohelix-substrate complex for controlling adhesion and polarization of macrophages, a manufacturing method thereof, and a method of controlling adhesion and polarization of macrophages by using the nanohelix-substrate complex, and the method of controlling adhesion and polarization of macrophages may temporally and reversibly control adhesion and phenotypic polarization of macrophages in vivo and ex vivo by controlling application/non-application of a magnetic field to the nanohelix-substrate complex.

Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.

Abstract: The present invention discloses a method for increasing absorbent capacity of a superabsorbent material (SAM) by treating the SAM with a selected salt or a combination of such salts. The selected salt(s) may interact with the polymer chain of the SAM through one or more absorbent capacity enhancement mechanisms. The absorbent capacity enhancement mechanism(s) between selected salt(s) and the SAM may lead to greater absorbent capacity of the SAM.

Abstract: A surgical suture provides a visual indication when the suture is subjected to excessive tension. The suture has an inner core at least partially covered by a segmented outer layer. The inner core is not visible when the suture is subjected to acceptable amounts of tension, but will become visible if the suture is subjected to unacceptable amounts of tension. The visibility of the inner core thus indicates to the surgeon or similar medical professional whether or not the suture is under acceptable tension.

Abstract: Systems and methods for assessing the effectiveness of a decontamination event to decontaminate a portion of at least one of skin or a covering of the skin of an individual. A dispensing apparatus is attachable to a water dispenser via a water dispenser interface. The dispensing apparatus to house an agent dispensing system and a light source. The light source to emit light in accordance with a predetermined field of view, and to emit the light at a sufficient intensity and wavelength to cause a fluorescent agent dispensed by the agent dispensing system to fluoresce. The field of view defines an inspection space in which the portion of the individual can be positioned to detect at least one of a presence or an absence of the fluorescent agent during the decontamination event.

Abstract: A far-ultraviolet (far-UVC) disinfection device including a light source positioned within a housing and configured to emit a far-UVC light having an output wavelength of between about 206 nanometers to about 230 nanometers. There are one or more subject detection sensors positioned configured to detect the presence of one or more subjects and a controller in communication with the light source and the one or more subject detection sensors. The controller is configured to receive detection data from the one or more subject detection sensors and determine whether one or more subjects are within a range of the far-UVC light emitted by the light source. The controller is further configured to cause the light source to emit or cease emitting far-UVC light based on the amount of time one or more subjects are within the range of the emitted. far-UVC light.

Abstract: Sterilization method using plasma for sterilizing objects, wherein it is provided to introduce the objects to be sterilized into a sterilization chamber (13) and covey toward the latter a flow of air coming from a feed pipe (17) on which a plasma generator device (12) is disposed able to generate one or more gaseous compounds comprising a mixture of reactive oxygen species (ROS) and of reactive nitrogen species (RNS) so that the air is the carrier fluid which conveys the gaseous compounds toward the sterilization chamber (13); the method also provides to control the electric power used to produce the plasma as a function of the composition and/or the quantity of reactive species present in the sterilization chamber (13).

Abstract: An ozone treatment apparatus for grain uses first and second storage bins and an auger conveyor for conveying the grain from a first end in communication with the bottom of the first bin to a second end that can be directed into either one of the top of the first bin or the top of the second bin. An ozone injector injects ozone into the auger conveyor for mixing with and treating the conveyed grain. In a first mode, the conveyor discharges the grain from the second end of the conveyor through a first discharge outlet into the first storage bin to recycle the grain during treatment. In a second mode, the conveyor discharges the grain through a second discharge outlet into the second storage bin once treatment is complete.

Abstract: A portable sterilizer includes a housing in which a water tank is installed inside and a nozzle capable of spraying sterilizing water in a fog state is installed to be exposed to an outside on a side thereof, an ozone gas supply unit installed inside the housing and configured to supply ozone gas to the nozzle, a compressed air supply unit installed inside the housing and configured to supply compressed air to the nozzle, and a water supply unit installed inside the housing and configured to supply water from the water tank to the nozzle. The ozone gas and compressed air are supplied to the nozzle in a mixed gas state, the water is supplied directly to the nozzle, and the mixed gas and water are finally mixed inside the nozzle and then sprayed with sterilizing water in a fog state.

Abstract: A system for activating an emitting module is provided. A computer device identifies (i) environment data relating to an environment, and (ii) user data relating to a user located within the environment, wherein the user is wearing a wearable computing device. The computing device predicts that the user will interact with a surface in the environment based, at least in part, on the environment data and the user data. The computing device selects at least one emitting module from a plurality of emitting modules on the wearable device based, at least in part, on a predicted proximity of the at least one emitting module to the surface. The computing device prompts the user to activate the at least one emitting module.

Abstract: Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer.

Abstract: The invention relates to a cross-linkable polymer including a base polymer including functional groups at least some of which have been reacted with a first organic molecule including a cross-linkable unit and with a second organic molecule capable of bonding to organic and/or inorganic substrates. The invention further relates to a hydrogel including the cross-linkable polymer that includes cross-linkable polymer strands, wherein at least some of the cross-linkable units of different cross-linkable polymer strands have reacted to form a covalent bond thereby forming a covalently linked network. The invention further relates to a method for the preparation of the hydrogel and to the use of the hydrogel.

Abstract: Provided herein are scaffold biomaterials comprising a decellularised fungal tissue from which cellular materials and nucleic acids of the tissue are removed, the decellularised fungal tissue comprising a cellulose- or chitin-based 3-dimensional porous structure. Methods for preparing such scaffold biomaterials, as well as uses thereof as an implantable scaffold for supporting animal cell growth, for promoting tissue regeneration, for promoting angiogenesis, for a tissue replacement procedure, and/or as a structural implant for cosmetic surgery are also provided. Therapeutic treatment and/or cosmetic methods employing such scaffolds are additionally described.

Abstract: An inflated and suspension dried decellularized extracellular matrix of a mammalian organ or tissue, or a vascularized portion thereof, and methods of making and using the inflated and suspension dried material, are provided.

Abstract: The present disclosure is concerned with magneto-patterned cell-laden hydrogel materials and methods of making and using those materials. The disclosed materials are useful for, among other things, repair of tissue defects, e.g., tissue at a tissue interface such as a bone-cartilage interface.

Abstract: The present invention provides a scaffold for tissue regeneration and a method of manufacturing the same. The scaffold for tissue regeneration of the present invention includes grooves and ridges formed on one surface thereof, wherein the grooves or ridges have a plurality of nanopores formed thereon, thereby providing an environment suitable for attachment, differentiation, growth, and migration of cells. Therefore, the scaffold may be effectively used as a material for tissue regeneration.

Abstract: The present disclosure provides an engineered collagen composition comprising collagen, wherein the collagen composition is compressed to form a gradient of at least one physical property. Methods of using and of manufacturing the engineered collagen compositions of the present disclosure are also provided.

Abstract: A system for disrupting a biofilm on a medical device that comprises an implantable medical device; a magnetically-sensitive coating on the surface of the implantable device comprising a polymer and magnetic particles embedded within the polymer; and a coil element capable of generating an alternating magnetic field, wherein the coil element is constructed and arranged to be capable of applying an alternating magnetic field to induce heating of the surface of the implantable device.

Abstract: Aspects of the disclosure include an attachment for providing a scent to a container. In some aspects, a scent delivery system includes a bottle including a collar and a ledge structure each extending circumferentially outward; a scent ring loaded with a volatile chemical agent to emanate and generate a scent and including an interior protruding structure projecting from an interior wall of the ring, the scent ring configured to fasten around the neck of the bottle based on contact between the interior protruding structure and the ledge structure of the bottle; and a cap reversibly attachable to the bottle and including an interior rim structure that circumferentially projects from the interior of the cap, where the cap is structured to enclose the scent ring in a compartment formed between the collar and the interior rim structure when the cap is securely fastened to the bottle and trap the scent.

Abstract: A purifying method includes determining an intended position that ejected matter ejected from an ejecting apparatus is made to reach; judging whether an object touches the ejected matter within a period of time from ejection of the ejected matter from the ejecting apparatus to reaching of the ejected matter to the intended position based on positional information on the object, the positional information being obtained by a first sensor; and controlling, based on a result of the judging, how the ejecting apparatus ejects the ejected matter into an area including the intended position.

Abstract: Systems and methods include a heat transfer body with opposing major surfaces formed from a thermally conductive substrate in intimate thermal interaction with an alumina exterior surface that extends across the major surfaces of the body. In an illustrative example, the heat source may be a substantially planar, silicone-based heater source (P-SBHS). The heat transfer body may be configured to thermally interact, for example, heat from a heat source proximate a first of the major surfaces to a second of the major surfaces. A temperature sensor module may be located, for example, proximate to the first major surface such that a temperature sensor thermally interacts with the first major surface. The temperature sensor module may, for example, insulate the temperature sensor from the P-SBHS.

Abstract: A thermal protection system configured for use with a dialysate container or bag in a dialysis system is disclosed. The thermal protection system being configured so that when the dialysate container is subjected to a temperature greater than a predetermined temperature such as, when the dialysate container is heated within a microwave oven, the thermal protection system is configured to (i) prevent the flow of dialysate from the bag, (ii) indicate that the dialysate container has been subjected to a temperature greater than the predetermined temperature, or (iii) a combination thereof. In one embodiment, the thermal protection system is a circular hollow ring positioned within an exit port of the bag, the ring melting upon reaching the predetermined temperature to block the flow of dialysate. Alternatively, and/or in addition, the thermal protection system may be a thermally sensitive dye configured to change color upon being subjected to the predetermined temperature.

Abstract: Gaseous nanobubbles are created and infused into the blood stream to therapeutic effect such as oxygenation. The nanobubbles may be created inside or outside of the patient, either during infusion or prior to infusion. CO2 is extracted from the blood to improve oxygen.

Abstract: The present invention relates to a method and to an apparatus for continuously monitoring the membrane coupling in a pressure measurement system in a extracorporeal circuit of a blood treatment machine. The invention enables the continuous monitoring of the functionality of the pressure measurement system without an interruption of any blood treatment being necessary.

Abstract: A light irradiation device includes: a flow channel through which blood or a blood component flows; and an LED lamp which irradiates the blood or the blood component flowing through the flow channel with light so as to inactivate a virus included in the blood or the blood component, in which a multilayer structure in which a plurality of the flow channels is arranged in parallel is formed.

Abstract: An operational unit for locating and neutralizing pathogen cells in blood includes a cassette which has a plurality of thin holding chambers that are filled with blood drawn from a patient. A light source illuminates the holding chambers and passes light to an underlying sensor array such that the cells in the blood selectively block the light to produce shadow images of the cells. A processor performs pattern recognition to locate the pathogen cells by use of an image library. After the pathogen cells are located, a source of ultraviolet light is activated and UV light is passed through selectively controlled shutters to illuminate only the limited areas that have the identified pathogen cells. Sufficient ultraviolet light energy is applied to destroy the identified cells. A pump refills the cassette holding chambers, returns the neutralized-pathogen blood to the patient, and the process is repeated.

Abstract: Systems and methods are provided for a bodily fluid management system for pumping bodily fluid such as lymph. The bodily fluid management system may include an implantable pump with a rotor having a magnetic portion and inlet and outlet tubes that connect to a fluid chamber. The fluid chamber has a volume that can be selectively reduced or increased via the rotor. The rotor is designed to periodically open and close kinking valves at each of the inlet and outlet tube to permit bodily fluid to enter the fluid chamber during an intake cycle and exit the fluid chamber during a discharge cycle. The magnetic portion of the rotor may be caused to rotate by an external controller that is positioned outside of the body and adjacent to the pump. The external controller may have a magnet that magnetically interfaces with the rotor to cause the rotor to rotate.

Abstract: A liquid-collection canister includes a liquid collection chamber defined by at least one wall and a first and second gas-communication pathway formed within the at least one wall. A first aperture is positioned between the first gas-communication pathway and the liquid collection chamber to allow gaseous communication between the liquid collection chamber and the first gas-communication pathway. A second aperture is positioned between the second gas-communication pathway and the liquid collection chamber to allow gaseous communication between the liquid collection chamber and the second gas-communication pathway. A first and a second liquid-air separator are positioned over the first aperture and the second aperture, respectively, to substantially prevent liquid passing through the first and second apertures.